From Beverages to Biotech: Splash's High-Stakes Bet on Cannabinoid Medicine

FORT LAUDERDALE, Fla., June 15, 2026 – Splash Beverage Group, a company whose portfolio once included wine, tequila, and performance drinks, today announced a CDN$300,000 investment in cannabinoid biopharmaceutical firm Avicanna. The move marks the first tangible step in a radical and risky transformation, pivoting the struggling beverage company toward the complex, highly regulated world of cannabinoid healthcare. While the press release frames it as a strategic allocation, a deeper look reveals a move born from existential necessity—a bet on a new industry as its old one collapses.

A Pivot Born from Peril

Splash Beverage Group's leap into biopharmaceuticals is less a strategic expansion and more a desperate grasp for a lifeline. The company's recent financial history paints a grim picture. After seeing revenue plummet over 90% from $0.8 million in 2024 to a mere $70,000 in 2025 due to a self-admitted "lack of operating capital" and "unsuccessful commercialization efforts," the company's survival has been in question.

Filings reveal a company that generated minimal revenue in the first quarter of 2026 and none at all in the second after a key customer contract was terminated. With cash reserves dwindling to just over $380,000 by the end of March and a net loss of $25.2 million in 2025, Splash issued a "substantial doubt about its ability to continue as a going concern." This distress was compounded by a non-compliance notice from the NYSE American exchange in April regarding its shareholders' equity. The days of promoting brands like Copa Di Vino and TapouT Performance Drink are definitively over.

Enter Brady Cobb, appointed Interim CEO in May 2026. Cobb, a veteran of the cannabis sector with a track record of founding and leading cannabis companies, is steering the ship in a completely new direction. The investment in Avicanna is the first shot fired in this new campaign. "As we evaluated opportunities across the sector, Avicanna stood out," Cobb stated in the official announcement, signaling that this pivot is a calculated one, despite the company's precarious position.

The Blueprint for Cannabinoid Healthcare?

If Splash is placing a bet, it appears to have chosen its horse carefully. Avicanna is not a speculative startup but a commercial-stage biopharmaceutical company with a clear, science-first strategy that deliberately avoids the volatile recreational cannabis market. Its business model is far closer to a specialty pharma company than a typical cannabis firm, a distinction that likely attracted Splash's new leadership.

Avicanna's reported revenue of $25.5 million in 2025, coupled with expanding gross margins and near break-even adjusted EBITDA, stands in stark contrast to Splash's financial state. The company's success is built on a multi-pronged platform that Splash is now buying a small piece of. This includes Trunerox™, a proprietary CBD-based oral drug for severe epilepsy that has already received marketing authorization in Colombia—a critical milestone demonstrating an ability to navigate a pharmaceutical regulatory process.

Furthermore, Avicanna's MyMedi.ca platform is a significant revenue driver, accounting for 80% of its 2025 revenue. The platform serves as a comprehensive ecosystem for medical cannabis, offering pharmacist-led care, insurance adjudication support, and a marketplace of over 200 products. This infrastructure, which Cobb praised for its "healthcare-system integration," represents a mature operational model that would take years and millions of dollars for a newcomer to replicate. Avicanna's focus on intellectual property, with multiple patents pending and research conducted at world-class facilities, further solidifies its position as a leader in evidence-based cannabinoid medicine.

Medicine, Not Marijuana: A Market in Metamorphosis

The Splash-Avicanna deal serves as a microcosm of a much larger industry trend: the maturation of cannabis from a recreational product into a source of clinically validated medicine. The future growth in the cannabinoid sector is widely expected to come from the pharmaceutical segment, which is projected to account for nearly 60% of the medical market value in 2026. Global market forecasts predict the medical cannabinoid sector could grow from around $30 billion today to nearly $200 billion by 2034, driven by an aging population, increasing acceptance by the medical community, and a desperate search for non-opioid pain solutions.

This new landscape demands a different kind of company. The winners will not be those with the flashiest branding, but those with the most robust clinical data, the most defensible intellectual property, and the ability to navigate complex regulatory frameworks like those managed by Health Canada and the FDA. Avicanna has spent nearly a decade building its platform within Canada's federally regulated medical system, one of the most advanced in the world. As Cobb noted, "In many respects, Avicanna has built and operated within a federally regulated medical cannabinoid framework that already incorporates many of the characteristics increasingly being evaluated across the United States healthcare system."

The Price of Reinvention

The CDN$300,000 investment gives Splash 2 million shares and 1 million warrants in Avicanna, a modest entry fee for a foothold in a high-growth industry. For a company with limited cash, it's a capital-light way to acquire access to a validated platform and pivot its entire corporate narrative. The upside is clear: if Avicanna continues its growth and Splash can leverage this partnership to attract new capital and build its wellness platform, the investment could be transformative.

However, the risks remain immense, primarily within Splash itself. The company still faces substantial dilution risk. Its survival is contingent on raising more capital, likely through its existing equity line of credit, which could flood the market with new shares and devalue existing holdings. The success of this dramatic pivot depends not only on Avicanna's performance but on Brady Cobb's ability to convince the market that Splash Beverage Group can successfully transform from a failing beverage company into a savvy biotech investor and platform builder.